spacer
home > ebr > autumn 2017 > revamping regulations
PUBLICATIONS
European Biopharmaceutical Review

Revamping Regulations

Stem cell products hold great promise for multiple clinical indications and are actively studied in clinical trials (1). However, many related safety features raise concerns and currently generate extensive and costly testing of the final product, if intended for clinical use. The regulatory expectations for stem cell testing for clinical studies, as well as marketing authorisation applications, are not entirely clear, up-to-date or detailed. Furthermore, differences between US and EU guidance, in this respect, hamper the current development of products for EU markets.

Risk Profiling

Stem cells used for therapeutic purposes include a wide variety of cells with different type differentiation capacities, spanning from restricted multipotent up to pluripotent stem cells (2). Hematopoietic stem cells have been widely used for ex vivo gene therapy of monogenic inherited diseases, and mesenchymal stem cells have been utilised – eg in treatment of Graft versus Host Disease – for more than a decade due to their immunomodulatory properties (3,4). Pluripotent stem cells, ie embryonic stem cells and induced pluripotent stem cells (iPSCs), are still in early clinical development, yet some clinical data are already available (5,6).

When considering possible risks of stem cells, several issues need to be considered, such as the donor (autologous versus allogeneic), characteristics of the cells, extent of manipulation, design of vectors for genetic modification, dose and the existing knowledge of the cell type/product to be used. One of the main concerns related to stem cell products is tumourigenicity. For pluripotent stem cells, teratoma formation is part of their natural characteristics, which calls for thorough control of the cell differentiation status before clinical use.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Paula Salmikangas, Director for Biopharmaceuticals and ATMPs, NDA Advisory Board, is a clinical biochemist by original training with a PhD in muscle cell biology. Since 2006, she has been an Adjunct Professor of Biochemistry for the University of Helsinki, Finland. Paula joined NDA in 2017, has served as a member of the EMA Committee for Advanced Therapies (CAT) from 2009 to 2017 and has been the Chair of the CAT 2014-2017. Her main areas of expertise are biological medicinal products, especially ATMPs, chemistry, manufacturing and controls aspects of biopharmaceuticals.
spacer
Dr Paula Salmikangas
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Business Continuity Plan - Message from Protagen Protein Services (PPS)

Following the recent COVID-19 outbreak, we at Protagen Protein Services (PPS) are preparing for all eventualities. Please be assured that PPS will continue to operate as normal providing you with all of the professional support and service you have to come to expect from us. Given the gravity of the situation, and to protect our staff, clients, and communities from the spread of the virus, we have taken various measures within a scope of a Business Continuity Plan:
More info >>

White Papers

Outsourcing and Insourcing: How Eurofins solves the bio/pharma industry’s challenges associated with meeting drug development timelines and budgets with restricted headcounts

Eurofins BioPharma Product Testing

Pharmaceutical and biopharmaceutical companies face a significant challenge to get their drug products developed and launched quickly, all while keeping development costs down. One of the most common ways for companies to lower development costs is to manage fixed headcounts. But when the same scope of work still needs to be completed by a designated time with fewer staff members, this presents a significant challenge. So, how do bio/pharma companies solve this ever so common challenge of increasing output while decreasing headcount? There are essentially three options: temporary staffing, outsourcing, or insourcing.
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement